Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ralph Tremaglio

Internal Medicine Naugatuck, CT Medical Doctor

NPI 1053360305 CMS profile 93167

305 Church St, Suite 6, Naugatuck, CT 06770

Open in the dashboard

General payments

$5,436

308 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ralph Tremaglio of Naugatuck, CT is reported in the CMS Open Payments database as having received $5,436 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $85 5
2024 General $1,412 71
2023 General $990 55
2022 General $839 47
2021 General $1,042 66
2020 General $717 43
2019 General $351 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ralph Tremaglio
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ralph Tremaglio were reported at $85. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ralph Tremaglio Internal Medicine median Middle half National median
2019 $351 $159 $48–$570 $163
2020 $717 $119 $33–$402 $114
2021 $1,042 $135 $37–$521 $132
2022 $839 $141 $42–$496 $149
2023 $990 $149 $45–$519 $160
2024 $1,412 $154 $47–$537 $164
2025 $85 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,718 89 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $841 45 payments
  3. AbbVie, Inc. $668 42 payments
  4. GlaxoSmithKline, LLC. $521 31 payments
  5. Novo Nordisk Inc $436 27 payments
  6. Lilly USA, LLC $404 26 payments
  7. Exact Sciences Corporation $244 9 payments
  8. Merck Sharp & Dohme Corporation $103 7 payments
  9. Eisai Inc. $73 6 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $60 4 payments
  11. Other $367 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,388 306 payments
  2. Education $48 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $908 46 payments
  2. BREZTRI $735 36 payments
  3. TRELEGY ELLIPTA $498 30 payments
  4. JARDIANCE Diabetes $431 22 payments
  5. Ozempic $376 24 payments
  6. SPIRIVA RESPIMAT $339 13 payments
  7. RYBELSUS $336 21 payments
  8. UBRELVY $288 18 payments
  9. JARDIANCE Diabetes $252 16 payments
  10. AREXVY $250 14 payments
  11. Other $2,971 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 169 drugs

Part D claims

8,260

Median for Internal Medicine: 777

Drug cost

$606,596

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 80 $76,213
Farxiga Dapagliflozin Propanediol Brand 50 $60,957
Januvia Sitagliptin Phosphate Brand 61 $60,621
Xarelto Rivaroxaban Brand 55 $52,988
Jardiance Empagliflozin Brand 41 $52,171
Tradjenta Linagliptin Brand 41 $41,656
Juluca Dolutegravir/Rilpivirine Brand 11 $36,281
Mounjaro Tirzepatide Brand 27 $27,854
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $24,916
Trulicity Dulaglutide Brand 20 $20,682

The 10 drugs with the highest cost, of 169 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$45,487

Of which drugs: $1,926

Medicare patients

190

Average age 74

Services billed

722

91 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 26%
Atrial fibrillation 19%
Heart failure 16%
COPD 12%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 25 25 $1,838

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $432
$432 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $157
$157 50 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $156
$156 36 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $140
$140 41 —
AREXVY
  • GlaxoSmithKline, LLC. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record